Orlando becomes the new technology development center for ApiJect Systems


On Wednesday, ApiJect Systems, a medical technology company that develops devices to administer pharmaceuticals, announced the launch of the ApiJect Technology Development Center in Orlando.

The new facility will focus on working with pharmaceutical companies to develop, engineer, and test new single-dose prefilled injectors made with the ApiJect Platform to fill and finish their injectable drugs.

The ApiJect Center is a place where the future of injection technology is being developed. According to ApiJect CEO Jay Walker, the Center will support ApiJect’s existing fill-finish lines at our manufacturing partner site in South Carolina, which can currently produce up to 540 million single-dose prefilled injectors every year.

As a result of their combined efforts, these facilities will help the United States better meet public health challenges such as syringe shortages and safety concerns. They will also help meet the urgent demand for additional fill-finish capacity due to this pandemic and future bioemergencies around the globe.

First phase construction was completed within 9 months and on budget. When completed, the ApiJect Center will have the necessary infrastructure to support device prototyping and development in accordance with the FDA’s current Good Manufacturing Practice regulations.

Additionally, there has been a great deal of discussion in recent years about the importance of shortening supply chains and bringing critical technology back to the United States, “Walker said. From the beginning of the pandemic, our U.S. government partners have emphasised the importance of this issue.

The ApiJect Center was established for precisely this reason. It’s just getting started, with a current floor space of 16,000 square feet. A two-year expansion of the ApiJect Center’s current footprint is in the works. Our current BFS machines will be augmented by an additional two when our expansion is completed. When it comes to the future of injectable device technology, Central Florida will be a major player.

The HHS Office of the Assistant Secretary for Preparedness and Response provided $9.6 million in funding to help build the ApiJect Technology Development Center. ASPR is in charge of federal health care and public health emergency preparedness, response, and recovery efforts.

“ASPR’s key priorities include strengthening our nation’s health supply chain and expanding domestic manufacturing capacity,” explained Assistant Secretary for Preparedness and Response Dawn O’Connell. Injectable vaccines and medicines must be prepared for future pandemics and health emergencies, and we are pleased to support ApiJect in its efforts to develop new and innovative approaches to filling, finishing, and delivering these vaccines and medicines.

It is anticipated that the Prefilled ApiJect Injector, a device built on the ApiJect Platform, will be the first device to use the ApiJect Platform to deliver medication to a patient. Filling containers in a sterile environment without human intervention is referred to as “Blow-Fill-Seal.” As an added convenience, the prefilled ApiJect Injector will support the attachment of optional components such as needle hubs.

Also read: NIST will be led by Laurie Locascio after Senate confirmation

Previous articleAmentum wins $260 million for an unmanned system in the defense sector
Next articleClearShark acquisition expands the company’s IT product portfolio
Zaid Quraishi
My name is Zaid Quraishi. I pride myself on being a meticulous and organized individual who has done his Bachelors in Medical Technology and currently pursuing my Master's in the same course from Sher-e-Kashmir Institute of Medical Sciences. I belong to the beautiful valley of Kashmir, and my hometown is Srinagar. I am the elder sibling of my younger brother. As far as my strengths are concerned, I am effectively communicative, optimistic, reliable, a team player, and time-efficient. My weaknesses are that I am an honest person and I tend to be blunt, and sometimes, I like to work alone. I am passionate about content writing, online gaming, and learning new things, especially languages (currently German). I have written two papers for my University degree, which helped me immensely in learning how to write effectively. I am confident in my writing skills, and I can effectively pour my thoughts out in writing and express myself so that the reader relates to it and is intrigued by the content. I love to play with my pet cat, and she is a darling to me. The thing that I dislike the most is being distracted when you are in the zone. Currently, I am a content writer in a dynamic work environment at Shouzy, ready to improve readers' satisfaction and increase retention levels.


Please enter your comment!
Please enter your name here